Clinical Hematology Department, ICO-Hospital Universitari Germans Trias i Pujol, José Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain.
Cytotherapy. 2012 Aug;14(7):823-9. doi: 10.3109/14653249.2012.681042. Epub 2012 Apr 27.
Failure in mobilization of peripheral blood (PB) stem cells is a frequent reason for not performing hematopoietic stem cell transplantation (HSCT). Early identification of poor mobilizers could avoid repeated attempts at mobilization, with the administration of pre-emptive rescue mobilization.
Data from the first mobilization schedule of 397 patients referred consecutively for autologous HSCT between 2000 and 2010 were collected. Poor mobilization was defined as the collection of < 2 × 10(6) CD34(+)cells/kg body weight (BW).
The median age was 53 years (range 4-70) and 228 (57%) were males. Diagnoses were multiple myeloma in 133 cases, non-Hodgkin's lymphoma in 114, acute myeloid leukemia or myelodysplastic syndrome in 81, Hodgkin's lymphoma in 42, solid tumors in 17 and acute lymphoblastic leukemia in 10. The mobilization regimen consisted of recombinant human granulocyte-colony-stimulating factor (G-CSF) in 346 patients (87%) and chemotherapy followed by G-CSF (C + G-CSF) in 51 (13%). Poor mobilization occurred in 105 patients (29%), without differences according to mobilization schedule. Diagnosis, previous therapy with purine analogs and three or more previous chemotherapy lines were predictive factors for poor mobilization. A CD34(+)cell count in PB > 13.8/μL was enough to ensure ≥ 2 × 10(6) CD34(+)cells/kg, with high sensitivity (90%) and specificity (91%).
The prevalence of poor mobilization was high, being associated with disease type, therapy with purine analogs and multiple chemotherapy regimens. The threshold of CD34(+) cell count in PB identified poor mobilizers, in whom the administration of immediate or pre-emptive plerixafor could be useful to avoid a second mobilization.
外周血(PB)干细胞动员失败是不能进行造血干细胞移植(HSCT)的常见原因。早期识别不良动员者可避免反复尝试动员,而进行预防性挽救性动员。
收集了 2000 年至 2010 年间连续进行自体 HSCT 的 397 例患者的首次动员方案数据。将采集的 < 2 × 10(6) CD34(+)细胞/kg 体重(BW)定义为不良动员。
中位年龄为 53 岁(范围 4-70),228 例(57%)为男性。诊断为多发性骨髓瘤 133 例,非霍奇金淋巴瘤 114 例,急性髓系白血病或骨髓增生异常综合征 81 例,霍奇金淋巴瘤 42 例,实体瘤 17 例,急性淋巴细胞白血病 10 例。动员方案包括重组人粒细胞集落刺激因子(G-CSF)在 346 例患者(87%)中,化疗后加用 G-CSF(C + G-CSF)在 51 例患者(13%)中。105 例患者(29%)发生不良动员,与动员方案无差异。诊断、先前嘌呤类似物治疗和 3 个或更多先前化疗方案是不良动员的预测因素。PB 中 CD34(+)细胞计数 > 13.8/μL 足以保证 ≥ 2 × 10(6) CD34(+)细胞/kg,具有高灵敏度(90%)和特异性(91%)。
不良动员的发生率较高,与疾病类型、嘌呤类似物治疗和多个化疗方案有关。PB 中 CD34(+)细胞计数的阈值可识别不良动员者,立即或预防性使用plerixafor 可能有助于避免第二次动员。